A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Kezar Life Sciences, Inc.
Regeneron Pharmaceuticals
Tempus AI
Vedanta Biosciences, Inc.
Eisai Inc.
Anaveon AG
Incyte Corporation
Incyte Corporation
University of California, San Diego
NRG Oncology
Biogen
Grupo Español Multidisciplinar de Melanoma
ImmunoGenesis
Kymab Limited
Incyte Corporation
Fred Hutchinson Cancer Center
Altor BioScience
National Cancer Institute (NCI)
Immodulon Therapeutics Ltd
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
NextCure, Inc.
Rutgers, The State University of New Jersey
Clinigen, Inc.
The Methodist Hospital Research Institute
Nektar Therapeutics
Nektar Therapeutics
Herlev Hospital
Grupo Español Multidisciplinar de Melanoma
Idera Pharmaceuticals, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
M.D. Anderson Cancer Center
Eisai Inc.
M.D. Anderson Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Pfizer
Incyte Corporation
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)